Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-12-06
2005-12-06
Sitton, Jehanne (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007100, C435S091100, C435S091200
Reexamination Certificate
active
06972170
ABSTRACT:
This invention provides a method for determining the aggressiveness of a prostate carcinoma comprising: (a) obtaining a sample of the prostate carcinoma; and (b) detecting the presence of p27 protein in the prostate carcinoma, the absence of p27 indicating that the prostate carcinoma is aggressive. This invention also provides a method for diagnosing a beign prostate hyperplasia comprising: (a) obtaining an appropriate sample of the hyperplasia; and (b) detecting the presence of the p27 RNA, a decrease of the p27 RNA indicating that the hyperplasia is beign. This invention provides various uses of p27 in prostate cancer. Finally, this invention also provides different marker for prostate cancer.
REFERENCES:
patent: 5688665 (1997-11-01), Massague et al.
patent: 6316208 (2001-11-01), Roberts et al.
patent: 2004/0053247 (2004-03-01), Cordon-Cardo et al.
patent: WO 9422478 (1994-10-01), None
patent: WO 9833450 (1998-08-01), None
patent: WO 9904238 (1999-01-01), None
patent: WO 9928749 (1999-06-01), None
patent: WO 9931140 (1999-06-01), None
patent: WO 0077258 (2000-12-01), None
Agus, D.B., et al., (1999) “Response of Prostate Cancer to Anti-Her-2
eu Antibody in Androgen-dependent and -independent Human Xenograft Models”,Cancer Res.59:4761-4764. (Exhibit 2).
Agus, D.B. et al., (1999) “Prostate Cancer Cell Cycle Regulators: Response to Androgen Withdrawal and Development of Androgen Independence”,J. Natl. Cancer. Inst.91:1869-1876. (Exhibit 3).
Aprikian, A.G., et al., (1994) “Immunohistochemical Determination of P53 Protein Nuclear Accumulation in Prostatic Adenocarcinoma”,Jrnl. of Urol.151:1276-1280. (Exhibit 4).
Campbell, M.J., et al., (1997) “Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3analogue involves the induction of p21waf1, p27kip1and E-cadherin”,Journal of Molecular Endocrinolgy19:15-27. (Exhibit 5).
Cohen, D.W., et al., (1994) “Expression of Transforming Growth Factor-α and the Epidermal Growth Factor Receptor in Human Prostate Tissues”,J. Urol.152:2120-2124. (Exhibit 6).
Cordon-Cardo C., et al., (1998) “Distinct Altered Patterns of p27KIP1Gene Expression in Benign Prostatic Hyperplasia and Prostatic Carcinoma”,J. Natl. Cancer Inst.90:1284-1291, (Exhibit 7).
Cote, R.J., et al., (1998) “Association of p27Kip1Levels With Recurrence and Survival in Patients With Stage C Prostate Carcinoma”,J. Natl. Cancer Inst.90(12): 916-920. (Exhibit 8).
Di Cristofano, A., et al., (1998) “Pten is essential for embryonic development and tumour suppression”,Nature Genetics19:348-355. (Exhibit 9).
Hengst, L., et al., (1996) “Translational Control of p27Kip1Accumulation During the Cell Cycle”,Science271:1861-1864. (Exhibit 11).
Knudsen, K.E., et al., (1998) “Multiple G1Regulatory Elements Control the Androgen-dependent Proliferation of Prostatic Carcinoma Cells”,Journal of Biological Chemistry273 (32): 20213-20222. (Exhibit 12).
Kokontis, J.M., et al., (1998) “Progression of LNCaP Prostate Tumor Cells During Androgen Deprivation: Hormone-Independent Growth, Repression of Proliferation by Androgen, and Role for p27Kip1in Androgen-Induced Cell Cycle Arrest”,Molecular Endocrinology,12:941-953. (Exhibit 13).
Lacombe, L., et al., (1996) “Microsatellite Instability and Deletion Analysis of Chromosome 10 in Human Prostate Cancer”,Int. J. Cancer69:110-113. (Exhibit 14).
Lee, C.T., et al., (1999) “Overexpression of the Cyclin-dependent Kinase Inhibitor p16 is Associated with Tumor Recurrence in Human Prostate Cancer1”,Clin. Cancer Res.5:977-983. (Exhibit 15).
Osman, I., et al., (1997) “Chromosome 16 in Primary Prostate Cancer: A Microsatellite Analysis”,Int. J. Cancer71:580-584. (Exhibit 16).
Osman, I., et al., (1999) “Inactivation of the p53 Pathway in Prostate Cancer: Impact on Tumor Progression1”,Clinical Cancer Research5:2082-2088. (Exhibit 17).
Ponce-Castaneda, M.V., et al., (1995) “p27Kip1: Chromosomal Mapping to 12p12-12p13.1 and Absence of Mutations in Human Tumors”.Cancer Research55:1211-1214. (Exhibit 18).
Polyak, K., et al., (1994) “Cloning of p27Kip1, a Cyclin-Dependent Kinase Inhibitor and a Potential Mediator of Extracellular Antimitogenic Signals”,Cell78:59-66. (Exhibit 19).
Polyak, K., et al., (1994) “p27Kip1, a Cyclin-Cdk Inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest”,Genes&Development8:9-22. (Exhibit 20).
Scher, H.I., et al., (1995) “Changing Pattern of Expression of the Epidermal Growth Factor Receptor and Transforming Growth Factor α in the Progression of Prostatic Neoplasms1”,Clinical Cancer Research1:545-550. (Exhibit 21).
Silver, D.A., et al., (1997) “Prostate-specific Membrane Antigen Expression in Normal and Malignant Human Tissues1”,Clinical Cancer Research3:81-85. (Exhibit 22).
Simak, R., et al., (2000) “Expression of c-kit and kit-ligand in benign and malignant prostatic tissues”,Histol Histopathol15:365-374. (Exhibit 23).
Lloyd, et al., (1999) “A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers”, American Journal Pathology, 154(2):313-323. (Exhibit 1).
DeMarzo, A.M., et al. (1998) “Prostate Stem Cell Compartments: Expression of the Cell Cycle Inhibitor P27kip1 in Normal, Hyperplastic, and Neoplastic Cells”Amer. J. Path.153(3): 911-919 (Exhibit 3).
Fernandez, P.L. et al. (1999) “Expression of p27/kip1 is down-regulated in human prostate carcinoma progression”J. Path.187(5): 563-566 (Exhibit 4).
McArthur, J.G. et al. (1999) “Cancer Gene Therapy with Novel Chimeric P27/p16 Tumor Suppressor Genes”Proceed. Amer. Assoc. Cancer Res. Ann.40: 630 (Exhibit 5).
Aaltomaa, S. et al. (1999) “Prognostic Value and Expression of p21 (waf1/cip1) Protein in Prostate Cancer”The Prostate,39(1):8-15 (Exhibit 3).
Arai, Y. et al., (1997) “C-erbB-2 Oncoprotein: A Potential Biomarker of Advanced Prostate Cancer”Prostate,30(3):195-201 (Exhibit 4).
Baretton, G.B. et al. (1999) “Proliferation- and Apoptosis-Associated Factors in Advanced Prostatic Carcinomas Before and After Androgen Deprivation Therapy: Prognostic Significance of p21/WAF1/CIP1 Expression”British Journal of Cancer,80(3-4):546-555 (Exhibit 5).
Baselga, J. et al., (1998) “Recombinant Humanized Anti-HER2 Antibody (Herceptin TM) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin Against HER2
eu Overexpressing Human Breast Cancer Xenografts” 58(13):2825-2831 (Exhibit 6).
Cariou S. et al. (1998) “Prognostic Implication of Expression of the Cell Cycle Inhibitor Protein P27”,Breast Cancer Research and Treatment,1-3(52):29-41 (Exhibit 7).
Chen, Y. et al. (1998) “Increased Cell Growth and Tumorigenicity in Human Prostate LNCaP Cells by Overexpression to Cyclin D1”Oncogene,16(15):1913-1920 (Exhibit 8).
Craft, N. et al., (1999) “A Mechanism for Hormone-Independent Prostate Cancer Through Modulation of Androgen Receptor Signaling by the HER-2
eu tyrosine Kinase”Nature Medicine,5(3):280-285 (Exhibit 9).
Curnow, R.T. et al., (1997) “Clinical Experience With CD64-Directed Immunotherapy. An Overview”Cancer Immunology And Immunotherapy,45(3-4):210-15 (Exhibit 10).
Gumbiner, L. et al. (1999) “Overexpression of Cyclin D1 Is Rare in Human Prostate Carcinoma”Prostate,38(1):40-45 (Exhibit 12).
Han, E. et al., (1998) “Cyclin D1 Expression in Human Prostate Carcinoma Cell Lines and Primary Tumors”Prostate,35(2):95-101 (Exhibit 13).
James, N. et al., (1998) “Phase II Trial of the Bispecific Antibody MDX-H210 (Anti-Her2/Neu X Anti-CD64) Combined With GM-CSF In Patients With Advanced Prostate and Renal Cell Carcinomas That Express Her2/Neu”British Journal of Cancer,78(Suppl 2):19 (Exhibit 14).
Koenem
Cordon-Cardo Carlos
Koff Andrew
Scher Howard I.
Cooper & Dunham LLP
Sitton Jehanne
Sloan-Kettering Institute for Cancer Research
White John P.
LandOfFree
Markers for prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Markers for prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Markers for prostate cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3483146